Indeed, PARP inhibition in BRCA1 or BRCA2‐defective cancer cells leads to increased levels of mitotic aberrancies including chromatin bridges and micronuclei (Chan et al., 2018; Feng and Jasin, 2017; Laulier et al., 2011). The gene discussed is PARP1; the disease is cancer.